Showing results (21-30 of 57) with videos related to

Sort By:
Pageof 6
The Lancet. Haematology|June 12, 2026
Real-world patient-reported symptomatic adverse events and concordance with physician assessments after CAR T-cell therapy in patients with aggressive B-cell lymphomas: a prospective studyFabio Efficace, Pier Luigi Zinzani, Francesca Bonifazi, et al.
Cancers|February 15, 2022
Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela StudyBeatrice Casadei, Lisa Argnani, Alessandro Broccoli, et al.
British Journal of Cancer|September 27, 2017
Hepatitis C virus positive diffuse large B-cell lymphomas have distinct molecular features and lack BCL2 translocationsCarlo Visco, Jinfen Wang, Maria Chiara Tisi, et al.
British Journal of Haematology|December 23, 2024
Brexucabtagene autoleucel in-vivo expansion and BTKi refractoriness have a negative influence on progression-free survival in mantle cell lymphoma: Results from CART-SIE studyFederico Stella, Annalisa Chiappella, Martina Magni, et al.
Hemasphere|November 18, 2022
Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based TherapyLisa Argnani, Alessandro Broccoli, Cinzia Pellegrini, et al.
Hemasphere|January 25, 2020
Isavuconazole in Hematological Patients: Results of a Real-Life Multicentre Observational Seifem StudyChiara Cattaneo, Alessandro Busca, Doriana Gramegna, et al.
British Journal of Haematology|December 21, 2022
SARS-CoV-2 infection and vaccination in patients with hairy-cell leukaemiaEnrico Tiacci, Alessandro Mancini, Monia Marchetti, et al.
Blood|December 16, 2010
The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphomaDavide Rossi, Silvia Rasi, Alice Di Rocco, et al.
Haematologica|May 29, 2025
CAR T expansion and systemic inflammation: diverging impacts on large B-cell lymphoma therapy in the multicenter CART SIE studyMartina Magni, Sadhana Jonnalagadda, Francesca Bonifazi, et al.
Blood|July 7, 2023
Lenalidomide plus rituximab for the initial treatment of frail older patients with DLBCL: the FIL_ReRi phase 2 studyGuido Gini, Monica Tani, Alessandra Tucci, et al.
Pageof 6